Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 6/20 | 0.49 |
| ▸ | SLC6A11 | P48066 | 4/20 | 0.47 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.41 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10022830 | 1.00 | KIF11 (0.49) | KIF11SLC6A11SLC6A1KCNH2CA4 | |
| SCHEMBL6891571 | 0.90 | KIF11 (0.48) | KIF11SLC6A11SLC6A1KCNH2CA4 | |
| SCHEMBL18803715 | 0.86 | KIF11 (0.52) | KIF11SLC6A11SLC6A1KCNH2CA4 | |
| SCHEMBL14879264 | 0.86 | KIF11 (0.52) | KIF11SLC6A11SLC6A1KCNH2CA4 | |
| SCHEMBL4012213 | 0.86 | KIF11 (0.63) | KIF11SLC6A1 | |
| SCHEMBL2985182 | 0.83 | KIF11 (0.49) | KIF11SLC6A11SLC6A1KCNH2CA4 | |
| SCHEMBL992028 | 0.83 | SLC6A11 (0.50) | KIF11SLC6A11SLC6A1KCNH2MEN1 | |
| SCHEMBL9215766 | 0.83 | KIF11 (0.49) | KIF11SLC6A11SLC6A1KCNH2CA4 | |
| SCHEMBL16197752 | 0.83 | KIF11 (0.50) | KIF11SLC6A11SLC6A1KCNH2CA4 | |
| SCHEMBL2490823 | 0.83 | KIF11 (0.73) | KIF11SLC6A11SLC6A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050123533-A1 | Prodrugs activated by targeted catalytic proteins | WELLSTAT BIOCATALYSIS, LLC | 2005-06-09 | — | — | US | disclosed |
| US-6702705-B1 | Prodrugs activated by targeted catalytic proteins | IGEN INTERNATIONAL, INC. | 2004-03-09 | — | — | US | disclosed |
| EP-1261614-B1 | METHOD FOR THE PRODUCTION OF PERBENZYLATED 1-O GLYCOSIDES | SCHERING AG (DE) | 2004-01-07 | — | — | EP | disclosed |
| US-20030096765-A1 | Prodrugs activated by targeted catalytic proteins | IGEN, INC. | 2003-05-22 | — | — | US | disclosed |
| US-6545135-B2 | Alkylation | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-08 | — | — | US | disclosed |
| US-20020002274-A1 | Process for the production of perbenzylated 1-0-glycosides | SCHERING AKTIENGESELLSCHAFT | 2002-01-03 | — | — | US | disclosed |
| US-6258360-B1 | BENZOATE CONJUGATES; ANTITUMOR AGENTS | IGEN INTERNATIONAL, INC. | 2001-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050123533-A1 | Prodrugs activated by targeted catalytic proteins | DNPH1, DNPEP, PNP | KIF11 4678/4885SLC6A11 4844/4885SLC6A1 4763/4885 |
| US-20030096765-A1 | Prodrugs activated by targeted catalytic proteins | DNPH1, DNPEP, PNP | KIF11 4678/4885SLC6A11 4844/4885SLC6A1 4763/4885 |
| US-20020002274-A1 | Process for the production of perbenzylated 1-0-glycosides | STT3B, MAN1B1, OSTC | KIF11 3079/4885SLC6A11 1851/4885SLC6A1 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.